Investments, Funding & Disinvestment

Cambridge Health Saudi Arabia expects its licensed capacity to approach 500 beds once ongoing expansion projects at Cambridge Hospital Jeddah are completed and additional beds at Cambridge Hospital Dhahran receive regulatory approval.

The approval authorises the company to collect plasma in Indonesia and process it through its global manufacturing network while the country develops its own plasma infrastructure.

The investment package was launched in collaboration with the Ministry of Health and the Public Authority for Special Economic Zones and Free Zones.

The agreements were signed during a ceremony attended by senior government officials, including Bahrain’s Minister of Education, Dr Mohammed Mubarak Juma, and Saudi Fund for Development (SFD) Chief Executive Officer Sultan Al Marshad.

The agreement was signed by Total CX Interim Chief Executive Officer Aseel Mattar and Ibn Al Nafees Hospital Chief Executive Officer Rahma Jaberi during a ceremony in Bahrain.

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.

The agreement gives Apollo-managed funds and affiliates a non-controlling interest in a newly created entity that will hold Bayer’s LARC portfolio.

MindRank developed MAP as an AI-native drug discovery engine that combines computational biology, chemistry, laboratory experiments and clinical data into a single research platform.

The investment will fund the construction of a new 500,000-square-foot manufacturing facility, along with extensive upgrades to the company’s existing 700,000-square-foot plant in Austin, Texas.

Arprim Consultants presented a master plan and feasibility study led by Principal Architect Jared Momanyi, which sets out a phased approach to meet rising regional healthcare needs.